R

Renstar Medical Research | Ocala, FL

Research site
(Unclaimed)
Location
21 NE 1st Avenue, Ocala, Florida, United States of America
Site insights

Top conditions

Alzheimer Disease (41 trials)

Psoriasis (37 trials)

Migraine Disorders (13 trials)

Parkinson Disease (12 trials)

Osteoarthritis (11 trials)

Top treatments

Apremilast
Tanezumab
LY3857210
Pregabalin
Guselkumab
LY3556050
Bapineuzumab
LY3526318
Gantenerumab
Risankizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

37 of 192
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD)....

Active, not recruiting
Parkinson Disease
Drug: NLY01
Drug: Vehicle

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-s...

Enrolling
Chronic Low-back Pain
Diabetic Neuropathic Pain
Drug: LY3526318 ISA
Drug: LY3857210 ISA

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Placebo (semaglutide)
Drug: Semaglutide

This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 dia...

Enrolling
Obesity
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Insuline glargine U100 (reduced)

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participan...

Active, not recruiting
Overweight
Type 2 Diabetes Mellitus
Drug: Cagrilintide
Drug: Placebo cagrilintide

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmo...

Enrolling
Systemic Sclerosis With Lung Involvement
Idiopathic Pulmonary Fibrosis
Drug: Vixarelimab
Drug: Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Enrolling
Alzheimer's Disease
Mental Disorders
Drug: Donanemab
Drug: Placebo

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheime...

Active, not recruiting
Alzheimer Disease
Cognitive Dysfunction
Drug: Placebo
Drug: JNJ-63733657

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: LY3372689
Drug: Placebo
Locations recently updated

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-rela...

Active, not recruiting
Overweight or Obesity
Overweight
Drug: Placebo
Drug: Orforglipron
Locations recently updated

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's d...

Enrolling
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weig...

Active, not recruiting
Overweight
Obesity
Drug: Tirzepatide
Drug: Placebo

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Enrolling
Alzheimer's Disease (AD)
Drug: Placebo
Drug: ABBV-916

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

Active, not recruiting
Psoriasis
Other: Placebo
Drug: BMS-986322

Trial sponsors

Lilly logo

Lilly (39 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems